Table 2.
Temporal trend of the prescription of DOACs and VKA for patients with AF by CHA2DS2VASc score, 2011–2018
| Year | Number of AF patients prescribed with OAC (%) | DOAC |
VKA |
||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| CHA2DS2-VASc score |
CHA2DS2-VASc score | ||||||||||
| 0 | 1 | 2 | >2 | Total | 0 | 1 | 2 | >2 | Total | ||
| 2011 | 20 575 (49.6) | 1 (0.2) | 3 (0.2) | 3 (0.1) | 15 (0.1) | 22 (0.1) | 614 (99.2) | 1543 (99.5) | 3267 (99.5) | 15 062 (99.6) | 20 486 (99.6) |
| 2012 | 72 253 (51.3) | 7 (0.4) | 48 (0.9) | 79 (0.7) | 273 (0.5) | 407 (0.6) | 1858 (98.5) | 5227 (97.8) | 10 925 (98.4) | 53 165 (98.6) | 71 175 (98.5) |
| 2013 | 33 177 (54.4) | 36 (4.5) | 92 (4.0) | 164 (3.3) | 697 (2.8) | 989 (3.0) | 756 (95.3) | 2222 (95.4) | 4832 (96.2) | 24 227 (96.8) | 32 037 (96.6) |
| 2014 | 30 720 (59.0) | 84 (12.9) | 238 (12.0) | 501 (10.6) | 2087 (8.9) | 2910 (9.5) | 566 (86.8) | 1737 (87.8) | 4205 (89.1) | 21 233 (90.9) | 27 741 (90.3) |
| 2015 | 53 449 (64.9) | 264 (25.5) | 845 (23.8) | 1636 (19.3) | 7380 (18.3) | 10 125 (18.9) | 769 (74.3) | 2704 (76.0) | 6808 (80.3) | 32 885 (81.4) | 43 166 (80.8) |
| 2016 | 65 623 (68.3) | 618 (47.7) | 1753 (39.5) | 3666 (35.7) | 15 556 (31.4) | 21 593 (32.9) | 677 (52.3) | 2680 (60.3) | 6595 (64.2) | 33 977 (68.5) | 43 929 (66.9) |
| 2017 | 75 754 (71.4) | 929 (63.9) | 2779 (54.9) | 5933 (49.4) | 25 688 (44.9) | 35 329 (46.6) | 524 (36.0) | 2264 (44.7) | 6044 (50.4) | 31 477 (55.0) | 40 309 (53.2) |
| 2018 | 65 865 (75.0) | 871 (74.9) | 2881 (66.5) | 6357 (61.6) | 28 635 (57.2) | 38 744 (58.8) | 289 (24.8) | 1446 (33.4) | 3944 (38.2) | 21 370 (42.7) | 27 049 (41.1) |
AF, atrial fibrillation; DOAC, non-vitamin K antagonist oral anticoagulant; OAC, oral anticoagulant; VKA, vitamin K antagonist.